Sorafenib effect on HCC survival depends on hepatitis status
For patients with advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival (OS) is dependent on patients' hepatitis status, according to a meta-analysis published online Jan. 3 in the Journal of Clinical Oncology.

Richard Jackson, from the Liverpool Cancer Trials Unit in the United Kingdom, and colleagues undertook an individual patient data meta-analysis of three prospective randomized trials in which sorafenib was the control arm. Data were included for 1,643 patients with advanced unresectable hepatocellular carcinoma who received sorafenib.

Read more at: http://medicalxpress.com/news/2017-01-sorafenib-effect-hcc-survival-hepatitis.html#jCp
Like
Comment
Share